Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant Staphylococcus aureus USA300
2024

CPDI-02 Increases Protection Against MRSA Infections in Mice

Sample size: 60 publication 10 minutes Evidence: high

Author Information

Author(s): Stewart Jason P., Sandall Caleb M., Parriott Jacob E., Curran Stephen M., McCulloh Russell J., Ronning Donald R., Phillips Joy A., Schroeder Robin, Neel Christy, Lechtenberg Kelly F., Cohen Samuel M., Alnouti Yazen, Daria Sohel, Smith D. David, Vetro Joseph A., Casolaro Vincenzo

Primary Institution: University of Nebraska Medical Center

Hypothesis

Does treatment with CPDI-02 increase curative protection against subcutaneous infection with CA-MRSA?

Conclusion

Single early-stage IM treatment with CPDI-02 may increase curative protection against infections caused by CA-MRSA.

Supporting Evidence

  • Repeat IM treatment with CPDI-02 decreased maximum abscess surface area by 58%.
  • Single IM treatment at 6 h post-challenge was as effective as repeat treatment.
  • CPDI-02 was tolerated at doses between 130 and 170 mg/kg.

Takeaway

Giving a special treatment called CPDI-02 to mice helps them fight off a bad germ that can cause skin infections.

Methodology

Female CD-1 mice were infected with CA-MRSA and treated with CPDI-02 via different routes to assess abscess size and infection resolution.

Potential Biases

Potential bias in treatment administration and measurement of outcomes.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Healthy female outbred CD-1 mice, aged 4-6 weeks.

Statistical Information

P-Value

0.0052

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/pharmaceutics16121621

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication